T Juul1,2, N J Battersby3,4, P Christensen1,2, A Z Janjua3,4, G Branagan5, S Laurberg1,2, K J Emmertsen1, B Moran3,4. 1. Department of Surgery - Section for Colorectal Surgery, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. 3. The Pelican Cancer Foundation, The Ark, Basingstoke, UK. 4. Department of Colorectal Surgery, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK. 5. Colorectal Surgery, Salisbury NHS Foundation Trust, Basingstoke, UK.
Abstract
AIM: Many patients having anterior resection for rectal cancer suffer from severe long-term bowel dysfunction, known as low anterior resection syndrome (LARS). The LARS score was developed in Denmark, and Swedish, Spanish and German versions have been validated. The aim of this study was to validate the English translation of the LARS score in British rectal cancer patients. METHOD: Rectal cancer patients who underwent an anterior resection in 12 UK centres received the LARS score questionnaire, the EORTC QLQ-C30 and a single ad hoc quality of life question. A subgroup of patients received the LARS score questionnaire twice. RESULTS: The response rate was 80% and 451 patients were included in the analyses. A strong association between LARS score and quality of life (convergent validity) was found (P < 0.01), discriminative validity was good (P < 0.02) and the test-retest reliability was high (intraclass correlation coefficient 0.83). CONCLUSION: The English translation of the LARS score has shown good psychometric properties comparable with recently published results from an international multicentre study. Thus, the English translation of the LARS score can be considered a valid and reliable tool for measuring LARS. Colorectal Disease
AIM: Many patients having anterior resection for rectal cancer suffer from severe long-term bowel dysfunction, known as low anterior resection syndrome (LARS). The LARS score was developed in Denmark, and Swedish, Spanish and German versions have been validated. The aim of this study was to validate the English translation of the LARS score in British rectal cancerpatients. METHOD:Rectal cancerpatients who underwent an anterior resection in 12 UK centres received the LARS score questionnaire, the EORTC QLQ-C30 and a single ad hoc quality of life question. A subgroup of patients received the LARS score questionnaire twice. RESULTS: The response rate was 80% and 451 patients were included in the analyses. A strong association between LARS score and quality of life (convergent validity) was found (P < 0.01), discriminative validity was good (P < 0.02) and the test-retest reliability was high (intraclass correlation coefficient 0.83). CONCLUSION: The English translation of the LARS score has shown good psychometric properties comparable with recently published results from an international multicentre study. Thus, the English translation of the LARS score can be considered a valid and reliable tool for measuring LARS. Colorectal Disease
Authors: Virginia Sun; Tracy E Crane; Samantha D Slack; Angela Yung; Sarah Wright; Stephen Sentovich; Kurt Melstrom; Marwan Fakih; Robert S Krouse; Cynthia A Thomson Journal: Contemp Clin Trials Date: 2018-03-19 Impact factor: 2.226
Authors: Juliane Kupsch; Thomas Jackisch; Klaus E Matzel; Joerg Zimmer; Andreas Schreiber; Anja Sims; Helmut Witzigmann; Sigmar Stelzner Journal: Int J Colorectal Dis Date: 2018-03-15 Impact factor: 2.571
Authors: Lisa J Herrinton; Andrea Altschuler; Carmit K McMullen; Joanna E Bulkley; Mark C Hornbrook; Virginia Sun; Christopher S Wendel; Marcia Grant; Carol M Baldwin; Wendy Demark-Wahnefried; Larissa K F Temple; Robert S Krouse Journal: CA Cancer J Clin Date: 2016-03-21 Impact factor: 508.702
Authors: Luis Miguel Jimenez-Gomez; Eloy Espin-Basany; Marc Marti-Gallostra; Jose Luis Sanchez-Garcia; Francesc Vallribera-Valls; Manuel Armengol-Carrasco Journal: Int J Colorectal Dis Date: 2016-01-29 Impact factor: 2.571
Authors: R Hompes; J A Cornish; I Vogel; N Reeves; P J Tanis; W A Bemelman; J Torkington Journal: Tech Coloproctol Date: 2021-04-01 Impact factor: 3.781